SCHEMBL31532

SCHEMBL31532

COC(=O)c1ccc(N)nc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.65
KDM4E B2RXH2 2/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
NNMT P40261 2/20 0.60
GABRP O00591 1/20 0.60
GABRD O14764 1/20 0.60
GABRA1 P14867 1/20 0.60
GABRB1 P18505 1/20 0.60
GABRG2 P18507 1/20 0.60
GABRB3 P28472 1/20 0.60
GABRA5 P31644 1/20 0.60
GABRA3 P34903 1/20 0.60
GABRA2 P47869 1/20 0.60
GABRB2 P47870 1/20 0.60
GABRA4 P48169 1/20 0.60
GABRE P78334 1/20 0.60
GABRA6 Q16445 1/20 0.60
GABRG1 Q8N1C3 1/20 0.60
GABRG3 Q99928 1/20 0.60
GABRQ Q9UN88 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29826707 1.00 MAPK1 (0.65) MAPK1KDM4EL3MBTL1NNMTGABRP
Hydrochloric Acid SCHEMBL2177614 0.98 MAPK1 (0.62) MAPK1KDM4EL3MBTL1NNMTGABRP
Tetrahydrofuran SCHEMBL28037003 0.87 MAPK1 (0.51) MAPK1KDM4EL3MBTL1NNMTGABRP
SCHEMBL7362601 0.87 MAPK1 (0.51) MAPK1KDM4EL3MBTL1NNMTGABRP
SCHEMBL5543060 0.86 MKNK1 (0.65) MAPK1KDM4EL3MBTL1NNMTGABRP
SCHEMBL2734773 0.83 CDK8 (0.53) MAPK1KDM4ENNMTGABRPGABRD
SCHEMBL2643803 0.81 NNMT (0.56) MAPK1KDM4EL3MBTL1NNMTGABRP
6-Aminonicotinamide SCHEMBL25343859 0.81 NNMT (0.85) KDM4EL3MBTL1NNMTGABRPGABRD
SCHEMBL13914474 0.81 NNMT (0.66) MAPK1KDM4EL3MBTL1NNMTGABRP
SCHEMBL30474684 0.81 MAPK1 (0.65) MAPK1KDM4EL3MBTL1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1808 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114998621-B SERS quantitative analysis method based on coffee ring concentration effect and image processing technology 嘉兴学院 2024-04-16 CN claimed
CN-114998621-A SERS quantitative analysis method based on coffee ring concentration effect and image processing technology 嘉兴学院 2022-09-02 CN claimed
CN-113816956-A Synthesis method of pexidaltinib 湖北工业大学 2021-12-21 CN claimed
CN-113429342-A Synthesis method of pexidaltinib intermediate 武汉格迪泰健康科技有限公司 2021-09-24 CN claimed
CN-110330488-A A kind of piroxicam haptens and its preparation method and application 深圳市易瑞生物技术股份有限公司 2019-10-15 CN claimed
US-8524774-B1 Topical two step polytherapy for treatment of psoriasis and other skin disorders CYMBIOTICS, INC. (US) 2013-09-03 US claimed
US-4316902-A Therapeutic compositions and vehicles for topical pharmaceuticals YU RUEY J 1982-02-23 US claimed
US-4252796-A ALUMINUM COMPOUNDS, ANTIINFLAMMATORY AGENTS YU RUEY J 1981-02-24 US claimed
US-20260146042-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2026-05-28 US disclosed
US-12630528-B2 Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof LG CHEM, LTD. (KR) 2026-05-19 US disclosed
CN-122036587-A Zalutst compound and application thereof in inhibiting MLL1-WDR5 interaction 暨南大学 2026-05-15 CN disclosed
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 US disclosed
US-12600729-B2 New-type benzazepine fused ring derivative SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) 2026-04-14 US disclosed
EP-4719385-A2 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS University of Vermont and State Agricultural College (US) 2026-04-08 EP disclosed
US-4310526-A Substituted 6,7-methylene pyrido[1,2-a]pyrimidines useful as anti-allergic and anti-ulcer agents FARMITALIA CARLO ERBA S.P.A. (IT) 1982-01-12 US disclosed
US-4284630-A Stabilized water-in-oil emulsions YU RUEY J 1981-08-18 US disclosed
US-4252796-A ALUMINUM COMPOUNDS, ANTIINFLAMMATORY AGENTS YU RUEY J 1981-02-24 US disclosed
US-4141977-A Treatment of psoriasis with 6-substituted nicotinamides, 2-substituted pyrazinamides and closely related compounds YU RUEY J 1979-02-27 US disclosed
US-4067975-A Treatment of psoriasis with 6-aminonicotinamide and thionicotinamide YU RUEY J 1978-01-10 US disclosed
US-4067975-A Treatment of psoriasis with 6-aminonicotinamide and thionicotinamide YU RUEY J 1978-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, CSNK2A1, CSNK2A2 MAPK1 1825/4885KDM4E 810/4885L3MBTL1 2459/4885
US-20260146042-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES CDK9, CDK6, CDK7 MAPK1 118/4885KDM4E 634/4885L3MBTL1 1901/4885
US-12630528-B2 Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof DGAT2, DGAT1, SOAT2 MAPK1 1783/4885KDM4E 2839/4885L3MBTL1 1846/4885
US-12600729-B2 New-type benzazepine fused ring derivative AVPR1B, AVPR2, AVPR1A MAPK1 1588/4885KDM4E 3354/4885L3MBTL1 1699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.